The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • ECS Botanics has been granted a Manufacture Licence for medicinal cannabis operations in Tasmania
  • The licence allows ECS to supply, manufacture, store and dispose of the drug
  • The company is currently waiting for its Cultivation Licence to complete the licensing plan for Tasmania
  • ECS is up 13.46 per cent on the ASX and is selling shares for 5.9 cents apiece

ECS Botanics has been granted a Manufacture Licence for medicinal cannabis operations in Tasmania.

The licence was granted by the Australian Federal Government’s Department of Health Office of Drug Control (ODC). It allows ECS to supply, manufacture, store and dispose of the drug.

ECS is an agribusiness and hemp food (wholesale and retail) company. It has the necessary licenses to cultivate, supply and manufacture industrial cannabis in Tasmania as well as a grower license in Queensland.

Managing Director Alex Keach is happy with the grant.

“This is a significant milestone for the company, and a great step to becoming a leading diversified cannabis company in Australia,” Alex said.

“We will now immediately commence a feasibility study, while we look forward to reporting on additional licensing and development milestones,” he added.

The license is valid from now until November 8, 2020.

To complete the licensing plan for the Tasmanian site, ECS is currently waiting for its Cultivation Licence from ODC, which has been summited and is under review.

The company said it will update the market on the Cultivation Licence when it has more information.

As the company is developing the proposed medicinal cannabis facility in Tasmania, ECS has appointed PharmOut to assist a feasibility study is delivered with respect to the facility.

PharmOut is an international consultancy group. It helps businesses design, build and operate medicinal cannabis cultivation and manufacturing facilities.

Last week, ECS announced that Woolworths will be stocking its Hemp Oil in stores from next year.

The company is up 13.46 per cent on the Australian Securities Exchange and is selling shares for 5.9 cents apiece at 12:36 pm AEDT.

ECS by the numbers
More From The Market Online

What it takes to get a new drug to market in Australia

In this latest version of Thematica from TMO, we're taking a break from mines and battery…

4DMedical partners with West Los Angeles VA Medical Center for Veteran lung imaging study

Respiratory imaging technology company, 4DMedical (ASX:4DX) has entered into a research agreement with the West Los…

Recce Pharma picks up Chinese patent for anti-infective drugs

Recce Pharmaceuticals (ASX:RCE) has confirmed its receipt of a patent in China to protect its class…

BlinkLab partnership with US smart-tech Turning Pointe raises hopes for autism kids

BlinkLab partners with US-based Turning Pointe Autism Foundation for clinical study ahead of its FDA registration…